Tacrobell tab_Phase1_PK

Phase 1

Completed

• Conditions: Immunosuppressant(Organ Transplantation, RA)
• Interventions: Drug: Prograf cap. 2mg; Drug: Tacrobell tab. 2mg

• Registration Number: NCT02336854
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

A randomized, open-label, two-way crossover study to assess the tolerability and pharmacokinetics of Tacrobell® Tab. and Prograf® Cap. after a single oral dose in healthy male volunteers.

Detailed Description

Not available

Study Timeline

• Status Verified: 2015-01
• Study First Submitted: 2015-01-08
• Study Start: 2015-01-12
• Study First Submitted QC: 2015-01-12
• Study First Posted: 2015-01-13
• Primary Completion: 2015-02-02
• Study Completion: 2015-03-19
• Last Update Submitted: 2017-08-07
• Last Update Posted: 2017-08-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 50

Inclusion Criteria

1. Understand the requirements of the study and voluntarily consent to participate in the study.
2. Healthy male volunteer in the age between 20 and 45 years old.
3. Body weight ≥ 55 kg and 30.0kg/m2 ≥ BMI ≥ 18.0kg/m2

Read More

Exclusion Criteria

1. presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, hematological, gastrointestinal, neurological, psychiatric or other diseases
2. any chronic disease which might interfere with resorption, distribution, metabolism or excretion of the drug, or major surgery of the gastrointestinal tract except for appendectomy
3. any history of drug hypersensitivity (especially to the active and inactive ingredients of the tacrolimus preparation)
4. administration of cyclosporine or Bosentan
5. administration of potassium sparing diuretic
6. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
7. SBP > 150 mmHg or< 90 mmHg
8. DBP > 100 mmHg or < 50 mmHg
9. positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies, RPR
10. AST or ALT > 1.5*ULN, e-GFR < 80 mL/min
11. history of drug abuse or positive drug screening test
12. intake or administration of any ethical or herbal medication medication within 2 weeks, intake or administration of any OTC or vitamin preparations
13. medication with metabolizing enzyme inducers or inhibitors such as barbitals within 1 month before first dosing
14. administration of another study medications within 3 months before first dosing
15. blood donation in 2 months, component blood donation within 1 month or blood transfusion before first dosing
16. Alcohol > 21 units/week or cannot stop drinking during the study
17. Cigarette > 10 cigarettes/day or cannot stop smoking during hospitalization
18. consumption of beverages or food containing caffeine(e.g.coffee, tea) during hospitalization
19. consumption of grapefruit or food containing grapefruit during hospitalization
20. Not eligible to participate for the study at the discretion of investigator.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Prograf cap. 2mg	Prograf cap. 2mg	1mg/capsule, PO, 2 capsule once daily for Period I \& II D1(crossover)
Tacrobell tab. 2mg	Tacrobell tab. 2mg	2mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)

Primary Outcome Measures

Name	Time	Method
AUClast	up to 96 hous postdose
Cmax	up to 96 hous postdose

Secondary Outcome Measures

Name	Time	Method
Tmax	up to 96 hous postdose
CL/F	up to 96 hous postdose
AUCinf	up to 96 hous postdose
t1/2	up to 96 hous postdose